Amended policy in Netherlands relating to patented indications

Basic information
Date of placement
72
0
0

Amended policy in Netherlands relating to patented indications The Pharma Letter The Dutch Medicines Evaluation Board (MEB) will no longer publish the full product information about the active substa

AmsterdamNews.net

The Dutch Medicines Evaluation Board (MEB) will no longer publish the full product information about the active substance of generic medicinal products on its website if an indication is still subject to a patent. This has been announced recently by the MEB in the news item Change in policy on patient information due to judgement by the European Court of Justice.

The new policy can be found on the page Patented indication. It states how marketing authorization holders can remove a patented indication from the product information.

After approval of the variation, the indication is no longer part of the marketing authorization and will no longer be listed in the SmPC (summary of product characteristics) and package leaflet. This is also the case when receiving the notification, depending on whether the product has been authorized via the national or decentralized/mutual recognition procedure. The MEB will then remove the patented indication from the Medicines Information Bank.

Within two weeks, the MEB will send a letter to the marketing authorization holders of generic medicinal products for which a patented indication is still included in the Medicines Information Bank. The marketing authorization holders do not need to wait for this letter. If a marketing authorization holder wishes to remove a patented indication from the product information, this can be done by submitting a variation or notification in accordance with the requirements included in the new policy.


(0)
0.0
Dislike 0
ОТН 0
Like 0
 
Someone is typing...
I agree and close
x Cookies text